|
| Status |
Public on Feb 03, 2021 |
| Title |
MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Immune checkpoint inhibitors (ICIs) have had a profound impact on the treatment of many tumors; however, their effectiveness against triple-negative breast cancers (TNBCs) has been limited. One factor limiting responsiveness of TNBCs to ICIs is a lack of functional tumor i-infiltrating lymphocytes (TILs) in ‘“non-inflamed’” or ‘“cold’” tumor immune microenvironments (TIMEs), albeitalthough by unknown mechanisms. Targeting MUC1-C in a mouse transgenic TNBC tumor model increases cytotoxic tumor -infiltrating CD8 + T cells (CTLs), supporting a role for MUC1-C in immune evasion. The basis for these findings and whether they extend to human TNBCs are not known.
|
| |
|
| Overall design |
Human TNBC cells (BT-549) silenced for MUC1-C using doxycycline inducible shRNAs were analyzed for the effects of MUC1-C on global transcriptional profiles.
|
| |
|
| Contributor(s) |
Kufe D, Liu S, Yamashita N, Long MD |
| Citation(s) |
33495298, 35681561, 36754452, 37821650, 38740827 |
| |
| Submission date |
Jan 02, 2021 |
| Last update date |
May 31, 2024 |
| Contact name |
Qiang Hu |
| E-mail(s) |
Qiang.Hu@RoswellPark.org
|
| Organization name |
Roswell Park Cancer Institute
|
| Street address |
Elm & Carlton Streets
|
| City |
Buffalo |
| State/province |
NY |
| ZIP/Postal code |
14263 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
| Samples (6)
|
|
| Relations |
| BioProject |
PRJNA689212 |
| SRA |
SRP300048 |
Less...
More...